search
Back to results

Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome

Primary Purpose

Climacteric Syndrome, Menopause

Status
Completed
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Amberen
Smart B
Placebo
Sponsored by
I.M. Sechenov First Moscow State Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Climacteric Syndrome focused on measuring Succinate, B complex vitamins, menopause

Eligibility Criteria

42 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female patients, 42-60 years of age;
  • Patient with diagnosis of "climacteric syndrome", in typical or non-complicated form, mild or moderate vegetative symptoms during menopause i.e. absence of menstrual period for at least 1 year;
  • Ability to read and understand informed consent form for the study's participation;
  • Patients without risk factors and changes in the breast tissue based on the mammogram;
  • Patients with medical history of risk factors without changes in the breast tissue;
  • Ability to adhere to the conditions of the study.

Exclusion Criteria:

  • Presence of female reproductive system cancers (breast cancer, cervical cancer etc.);
  • Presence of extragenital oncological conditions, except those in complete remission for 5 years or more;
  • Conditions requiring emergency or planned hospitalization in the next 6 months;
  • Presence of hormonally-active extragenital endocrine diseases (thyroid, adrenal, pituitary, hypothalamus);
  • Surgical interventions done on sex organs or breasts, 1 year or less prior to the screening;
  • Any surgeries done less than 3 months prior to the screening;
  • Patients receiving HRT;
  • Psychiatric conditions;
  • Diabetes;
  • Total ovariectomy
  • Patients taking any other dietary supplements that can affect climacteric syndrome within the last month before enrolling in the study

    • High risk of non-compliance

Sites / Locations

  • Sechenov First Moscow Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Amberen and Smart B

Placebo

Arm Description

Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months. SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen.

Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.

Outcomes

Primary Outcome Measures

Spilberger-Hanin (Situational anxiety)
The decrease of situational anxiety, measured as statistically significant reduction of the score in corresponding subscale
Spilberger-Hanin (Personal anxiety)
The decrease of personal anxiety, measured as statistically significant reduction of the score in corresponding subscale
Spilberger-Hanin (Actual anxiety)
The decrease of actual anxiety, measured as statistically significant reduction of the score in corresponding subscale. Actual anxiety as a sum of situational and personal anxiety scores was introduced by Hanin in his modification of original State-Trait Anxiety Inventory.
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (well-being)
Statistically significant reduction in designated symptom severity, compared between arms
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (activity)
Statistically significant reduction in designated symptom severity, compared between arms
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (mood)
Statistically significant reduction in designated symptom severity, compared between arms
Anxiety (measured by Hospital Anxiety and Depression Scale)
Statistically significant reduction in designated symptom severity, compared between arms
Depression (measured by Hospital Anxiety and Depression Scale)
Statistically significant reduction in designated symptom severity, compared between arms

Secondary Outcome Measures

"Heart beating quickly and strongly" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Feeling tense or nervous" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Difficulty in sleeping" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Excitable" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Attacks of panic" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Difficulty in concentrating" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Feeling tired or lacking in energy" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Loss of interest in most things" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Feeling unhappy or depressed" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Crying spells" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Irritability" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Feeling dizzy or faint" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Pressure or tightness in head or body" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Parts of body feeling numb or tingling" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Headaches" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Muscle or joint pains" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Loss of feeling in hands or feet" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
Breathing difficulties" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Hot flushes" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Sweating at night" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
"Loss of interest in sex" symptom (Greene Climacteric Scale)
Statistically significant reduction in designated symptom severity, compared between arms
Blood plasma estradiol levels, pg/ml
Statistically significant reduction in the levels, compared between arms
Weight, kg
Statistically significant reduction in the measurement, compared between arms

Full Information

First Posted
April 13, 2017
Last Updated
October 18, 2017
Sponsor
I.M. Sechenov First Moscow State Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT03118908
Brief Title
Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome
Official Title
Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen and Smart B by Women With Climacteric Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
April 24, 2017 (Actual)
Primary Completion Date
October 10, 2017 (Actual)
Study Completion Date
October 10, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
I.M. Sechenov First Moscow State Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate effectiveness and safety of combined use of dietary supplements Amberen and Smart B by women with a typical (without complications) form of climacteric syndrome, with mild to moderate symptoms.
Detailed Description
To evaluate effectiveness of combined use of dietary supplements Amberen and Smart B (vs placebo) by women with a typical (without complications) form of climacteric syndrome, with mild to moderate vegetative symptoms during perimenopause and menopause in regards to vasomotor, endocrine-metabolic, and neuro-psychological dysfunctions; To evaluate safety of combined use of dietary supplements Amberen and Smart B (vs placebo) by women with a typical (without complications) form of climacteric syndrome, with mild to moderate vegetative symptoms during perimenopause and menopause, lasting no less than 1 year in regards to vasomotor, endocrine-metabolic, and neuro-psychological dysfunctions; To develop recommendations for combined use of dietary supplements Amberen and Smart B for women with a typical (without complications) form of climacteric syndrome, with mild to moderate vegetative symptoms during perimenopause and menopause (menopausal for at least 1 year).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Climacteric Syndrome, Menopause
Keywords
Succinate, B complex vitamins, menopause

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
107 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Amberen and Smart B
Arm Type
Experimental
Arm Description
Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months. SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
Amberen
Intervention Description
Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
Intervention Type
Dietary Supplement
Intervention Name(s)
Smart B
Intervention Description
Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo capsules are identical to Amberen and Smart B capsules.
Primary Outcome Measure Information:
Title
Spilberger-Hanin (Situational anxiety)
Description
The decrease of situational anxiety, measured as statistically significant reduction of the score in corresponding subscale
Time Frame
week 12
Title
Spilberger-Hanin (Personal anxiety)
Description
The decrease of personal anxiety, measured as statistically significant reduction of the score in corresponding subscale
Time Frame
week 12
Title
Spilberger-Hanin (Actual anxiety)
Description
The decrease of actual anxiety, measured as statistically significant reduction of the score in corresponding subscale. Actual anxiety as a sum of situational and personal anxiety scores was introduced by Hanin in his modification of original State-Trait Anxiety Inventory.
Time Frame
week 12
Title
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (well-being)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (activity)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
WELL-BEING, LEVEL OF ACTIVITY, MOOD QUESTIONNAIRE (mood)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
Anxiety (measured by Hospital Anxiety and Depression Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
Depression (measured by Hospital Anxiety and Depression Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Secondary Outcome Measure Information:
Title
"Heart beating quickly and strongly" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Feeling tense or nervous" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Difficulty in sleeping" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Excitable" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Attacks of panic" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Difficulty in concentrating" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Feeling tired or lacking in energy" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Loss of interest in most things" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Feeling unhappy or depressed" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Crying spells" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Irritability" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Feeling dizzy or faint" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Pressure or tightness in head or body" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Parts of body feeling numb or tingling" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Headaches" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Muscle or joint pains" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Loss of feeling in hands or feet" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
Breathing difficulties" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Hot flushes" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Sweating at night" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
"Loss of interest in sex" symptom (Greene Climacteric Scale)
Description
Statistically significant reduction in designated symptom severity, compared between arms
Time Frame
week 12
Title
Blood plasma estradiol levels, pg/ml
Description
Statistically significant reduction in the levels, compared between arms
Time Frame
week 12
Title
Weight, kg
Description
Statistically significant reduction in the measurement, compared between arms
Time Frame
week 12

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
female
Minimum Age & Unit of Time
42 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female patients, 42-60 years of age; Patient with diagnosis of "climacteric syndrome", in typical or non-complicated form, mild or moderate vegetative symptoms during menopause i.e. absence of menstrual period for at least 1 year; Ability to read and understand informed consent form for the study's participation; Patients without risk factors and changes in the breast tissue based on the mammogram; Patients with medical history of risk factors without changes in the breast tissue; Ability to adhere to the conditions of the study. Exclusion Criteria: Presence of female reproductive system cancers (breast cancer, cervical cancer etc.); Presence of extragenital oncological conditions, except those in complete remission for 5 years or more; Conditions requiring emergency or planned hospitalization in the next 6 months; Presence of hormonally-active extragenital endocrine diseases (thyroid, adrenal, pituitary, hypothalamus); Surgical interventions done on sex organs or breasts, 1 year or less prior to the screening; Any surgeries done less than 3 months prior to the screening; Patients receiving HRT; Psychiatric conditions; Diabetes; Total ovariectomy Patients taking any other dietary supplements that can affect climacteric syndrome within the last month before enrolling in the study High risk of non-compliance
Facility Information:
Facility Name
Sechenov First Moscow Medical University
City
Moscow
ZIP/Postal Code
119991
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome

We'll reach out to this number within 24 hrs